Research Output per year
Fingerprint Dive into the research topics where Brian Jonas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 7 Similar Profiles
Acute Myeloid Leukemia
Medicine & Life Sciences
Co-Repressor Proteins
Medicine & Life Sciences
decitabine
Medicine & Life Sciences
Azacitidine
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Nuclear Receptor Co-Repressor 2
Medicine & Life Sciences
Hematopoietic Stem Cells
Medicine & Life Sciences
Alternative Splicing
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2004 2019
1
Citation
(Scopus)
Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma
Rosenberg, A., Brunson, A., Jonas, B., Keegan, T. H. & Wun, T., Jan 1 2019, In : Journal of the National Cancer Institute. 111, 1, p. 78-85 8 p.Research output: Contribution to journal › Article
Multiple Myeloma
Hematopoietic Stem Cells
Cell Survival
Stem Cells
Transplants
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia
Cortes, J. E., Jonas, B., Graef, T., Luan, Y. & Stein, A. S., Jan 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia.Research output: Contribution to journal › Article
Open Access
Azacitidine
Cytarabine
Acute Myeloid Leukemia
Safety
Asthenia
Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia
Lin, T-Y., Zhu, Y., Li, Y., Zhang, H., Ma, A. H., Long, Q., Keck, J., Lam, K., Pan, C-X. & Jonas, B., Aug 1 2019, In : Nanomedicine: Nanotechnology, Biology, and Medicine. 20, 102004.Research output: Contribution to journal › Article
Daunorubicin
Stem cells
Acute Myeloid Leukemia
Micelles
Leukemia
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia
Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. & Pollyea, D. A., Jan 1 2019, In : American Journal of Hematology.Research output: Contribution to journal › Review article
Open Access
Acute Myeloid Leukemia
Survival
Recurrence
Physiologic Monitoring
Therapeutics
1
Citation
(Scopus)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Cortes, J. E., Khaled, S., Martinelli, G., Perl, A. E., Ganguly, S., Russell, N., Krämer, A., Dombret, H., Hogge, D., Jonas, B., Leung, A. Y. H., Mehta, P., Montesinos, P., Radsak, M., Sica, S., Arunachalam, M., Holmes, M., Kobayashi, K., Namuyinga, R., Ge, N. & 3 others, , Jul 1 2019, In : The Lancet Oncology. 20, 7, p. 984-997 14 p.Research output: Contribution to journal › Article
Acute Myeloid Leukemia
Drug Therapy
Cytarabine
Intravenous Infusions
Survival